REDX.L Regulatory News (REDX)

REDX PHARMA PLC

("Redx" or the "Company")

Redx to host Virtual R&D Day on 11 October 2021

Alderley Park, UK, 5 October 2021 - Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, will host a Virtual R&D Day on 11 October 2021 at 1:00pm BST (8:00am EDT).

The R&D Day will include an update from the Company's leadership team on Redx's RXC004 programme and the potential of porcupine inhibition in Wnt-ligand driven colorectal, pancreatic and biliary cancers. There will also be an update on the Phase 1 study of RXC007, the Company's selective ROCK2 inhibitor, being developed for idiopathic pulmonary fibrosis.

The programme includes presentations from leading experts:

· Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Presentation Title: 'Potential of Porcupine Inhibition with RXC004 in Genetically Selected Patients with Metastatic MSS Colorectal Cancer'

· Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles

Presentation Title: 'Idiopathic Pulmonary Fibrosis'

· Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London

Presentation Title: 'The Importance of ROCK in Fibrosis'

To register for the webcast, please email redxpharma@fticonsulting.com. A recording of the webcast will be available on Redx's website after the event.

About Redx Pharma Plc 

Redx Pharma (AIM: REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in Phase 3 clinical studies in chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email alerts from Redx, please visit:

www.redxpharma.com/investor-centre/email-alerts/